Company / Capital Expenditures
Acadia Pharmaceuticals Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$4.7M
FY2025
5-year range
$0 / $4.7M
FY2021-FY2025
Trend
+796.7%
vs FY2024
Sector context
#74 of 194
Health Care
What the data says
Capital Expenditures changed +797% YoY in FY2025, a notable deviation from the 8-year average annual change of +275%.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of -9.2%.
Improved from $50,000 to $5M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Sector benchmark
#74 of 194 in Health CareTop 38% of 194This company $4.7M Sector average $117.5M
▼
-96.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, capital expenditures increased 796.7% year-over-year.
- Ranks #74 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.7M | +796.7% |
| FY2024 | $523.0K | +946.0% |
| FY2023 | $50.0K | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $1.1M | -85.2% |
| FY2020 | $7.6M | +572.0% |
| FY2019 | $1.1M | -46.3% |
| FY2018 | $2.1M | +159.1% |
| FY2017 | $812.0K | -46.1% |
| FY2016 | $1.5M | -29.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026